Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Phone206-432-9325
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$20.53 million
Profitability
Miscellaneous
Employees330
OptionableOptionable
Tilray (NASDAQ:TLRY) Frequently Asked Questions
What is Tilray's stock symbol?
Tilray trades on the NASDAQ under the ticker symbol "TLRY."
How were Tilray's earnings last quarter?
Tilray Inc (NASDAQ:TLRY) announced its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.08. The company had revenue of $10 million for the quarter, compared to the consensus estimate of $10.25 million. Tilray had a negative net margin of 121.22% and a negative return on equity of 60.74%. The company's revenue was up 85.2% compared to the same quarter last year. View Tilray's Earnings History.
When is Tilray's next earnings date?
What price target have analysts set for TLRY?
5 brokers have issued 12-month price objectives for Tilray's stock. Their forecasts range from $35.00 to $200.00. On average, they anticipate Tilray's share price to reach $124.25 in the next twelve months. This suggests a possible upside of 60.9% from the stock's current price. View Analyst Price Targets for Tilray.
What is the consensus analysts' recommendation for Tilray?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tilray.
Has Tilray been receiving favorable news coverage?
News articles about TLRY stock have been trending somewhat positive on Saturday, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Tilray earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the next several days.
Who are some of Tilray's key competitors?
Some companies that are related to Tilray include Actelion (ALIOF), Canopy Growth (CGC), Aurora Cannabis (ACB), STADA Arzneimittel (STDAF), USANA Health Sciences (USNA), Cronos Group (CRON), Foamix Pharmaceuticals (FOMX), Chromadex (CDXC), Mediwound (MDWD), Natural Alternatives International (NAII), China Jo-Jo Drugstores (CJJD), Pharmacyte Biotech (PMCB), Mannatech (MTEX), GLG Life Tech (GLGLF) and Cyanotech (CYAN).
Who are Tilray's key executives?
Tilray's management team includes the folowing people:
- Mr. Edward Wood Pastorius Jr., Chief Revenue Officer (Age 50)
- Mr. Brendan Kennedy, Pres, CEO & Director (Age 46)
- Mr. Mark Castaneda, CFO, Sec. & Treasurer (Age 53)
- Dr. Catherine Jacobson, Director of Clinical Research & Member of Medical Advisory Board
When did Tilray IPO?
(TLRY) raised $135 million in an initial public offering on Thursday, July 19th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.
When did the company's lock-up period expire?
Tilray's lock-up period expired on Tuesday, January 15th. Tilray had issued 9,000,000 shares in its initial public offering on July 19th. The total size of the offering was $153,000,000 based on an initial share price of $17.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Who are Tilray's major shareholders?
Tilray's stock is owned by many different of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.01%). Company insiders that own Tilray stock include Brendan Kennedy and Edward Wood Pastorius Jr. View Institutional Ownership Trends for Tilray.
Which major investors are buying Tilray stock?
TLRY stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Tilray stock in the last two years include Brendan Kennedy and Edward Wood Pastorius Jr. View Insider Buying and Selling for Tilray.
How do I buy shares of Tilray?
Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tilray's stock price today?
One share of TLRY stock can currently be purchased for approximately $77.20.
How big of a company is Tilray?
Tilray has a market capitalization of $7.77 billion and generates $20.53 million in revenue each year. Tilray employs 330 workers across the globe.
What is Tilray's official website?
How can I contact Tilray?
Tilray's mailing address is 1920 EASTLAKE AVENUE E., SEATTLE WA, 98102. The company can be reached via phone at 206-432-9325.
MarketBeat Community Rating for Tilray (NASDAQ TLRY)
MarketBeat's community ratings are surveys of what our community members think about Tilray and other stocks. Vote "Outperform" if you believe TLRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
